

DEBLASI UGO D  
Form 4  
May 04, 2007

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
DEBLASI UGO D

2. Issuer Name and Ticker or Trading Symbol  
APPLERA CORP [ABI/CRA]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
APPLERA CORPORATION, 301 MERRITT 7

3. Date of Earliest Transaction (Month/Day/Year)  
05/02/2007

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
Vice President and Controller

(Street)  
NORWALK, CT 06851-1070

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
\_\_\_\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount	(D)	Price
Applied Biosystems Group Common Stock	05/02/2007		M		895	A	\$ 17.98
Applied Biosystems Group Common Stock	05/02/2007		S <sup>(1)</sup>		18	D	\$ 31.01
Applied Biosystems	05/02/2007		S <sup>(1)</sup>		4	D	\$ 31
							3,161.9205
							3,143.9205
							3,139.9205

Edgar Filing: DEBLASI UGO D - Form 4

Group Common Stock							
Applied Biosystems Group Common Stock	05/02/2007	<u>S<sup>(1)</sup></u>	14	D	\$ 30.99	3,125.9205	D
Applied Biosystems Group Common Stock	05/02/2007	<u>S<sup>(1)</sup></u>	27	D	\$ 30.96	3,098.9205	D
Applied Biosystems Group Common Stock	05/02/2007	<u>S<sup>(1)</sup></u>	13	D	\$ 30.95	3,085.9205	D
Applied Biosystems Group Common Stock	05/02/2007	<u>S<sup>(1)</sup></u>	13	D	\$ 30.94	3,072.9205	D
Applied Biosystems Group Common Stock	05/02/2007	<u>S<sup>(1)</sup></u>	9	D	\$ 30.92	3,063.9205	D
Applied Biosystems Group Common Stock	05/02/2007	<u>S<sup>(1)</sup></u>	14	D	\$ 30.9	3,049.9205	D
Applied Biosystems Group Common Stock	05/02/2007	<u>S<sup>(1)</sup></u>	13	D	\$ 30.89	3,036.9205	D
Applied Biosystems Group Common Stock	05/02/2007	<u>S<sup>(1)</sup></u>	1	D	\$ 30.88	3,035.9205	D
Applied Biosystems Group	05/02/2007	<u>S<sup>(1)</sup></u>	19	D	\$ 30.87	3,016.9205	D

Edgar Filing: DEBLASI UGO D - Form 4

Common Stock							
Applied Biosystems Group Common Stock	05/02/2007	S <sup>(1)</sup>	37	D	\$ 30.86	2,979.9205	D
Applied Biosystems Group Common Stock	05/02/2007	S <sup>(1)</sup>	73	D	\$ 30.85	2,906.9205	D
Applied Biosystems Group Common Stock	05/02/2007	S <sup>(1)</sup>	90	D	\$ 30.84	2,816.9205	D
Applied Biosystems Group Common Stock	05/02/2007	S <sup>(1)</sup>	63	D	\$ 30.83	2,753.9205	D
Applied Biosystems Group Common Stock	05/02/2007	S <sup>(1)</sup>	53	D	\$ 30.82	2,700.9205	D
Applied Biosystems Group Common Stock	05/02/2007	S <sup>(1)</sup>	87	D	\$ 30.81	2,613.9205	D
Applied Biosystems Group Common Stock	05/02/2007	S <sup>(1)</sup>	137	D	\$ 30.8	2,476.9205	D
Applied Biosystems Group Common Stock	05/02/2007	S <sup>(1)</sup>	82	D	\$ 30.79	2,394.9205	D
Applied Biosystems Group Common	05/02/2007	S <sup>(1)</sup>	75	D	\$ 30.78	2,319.9205	D

Stock

Applied  
Biosystems  
Group  
Common  
Stock

05/02/2007

S<sup>(1)</sup>

36

D

\$  
30.77

2,283.9205

D

Applied  
Biosystems  
Group  
Common  
Stock

05/02/2007

S<sup>(1)</sup>

8

D

\$  
30.76

2,275.9205

D

Applied  
Biosystems  
Group  
Common  
Stock

05/02/2007

S<sup>(1)</sup>

9

D

\$  
30.75

2,266.9205

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
						Date Exercisable      Expiration Date	Title
				Code V (A) (D)			Amount or Number of Shares
Applied Biosystems Group Employee Stock Options-Right to Buy	\$ 17.98	05/02/2007		M	895	06/26/2000      06/26/2007	Applied Biosystems Group Common Stock

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
DEBLASI UGO D APPLERA CORPORATION 301 MERRITT 7 NORWALK, CT 06851-1070			Vice President and Controller	

## Signatures

/s/ Thomas P. Livingston, Attorney-In-Fact for Ugo D.  
DeBlasi

05/04/2007

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Reflects sale by independent third-party administrator under the issuer's Insider Diversification Program.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.